SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences:
Live webcasts of both events will be available under the ‘Investors & News’ section of the Finch website. Replays of the webcasts will be available on Finch’s website for approximately 30 days after each event.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is exploring strategic options to potentially advance the development of its pre-clinical candidates FIN-524 for ulcerative colitis and FIN-525 for Crohn's disease and its pre-clinical program in autism spectrum disorder. Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & News” section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.69 |
| Daily Change: | 9.89 549.44 |
| Daily Volume: | 5,850 |
| Market Cap: | US$18.820M |
May 10, 2023 March 23, 2023 November 10, 2022 September 01, 2022 | |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE